 Wendy Kohrt
Concepts (663)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 45 | 2024 | 463 | 6.990 |
Why?
| | Exercise | 68 | 2024 | 1928 | 5.310 |
Why?
| | Body Composition | 54 | 2024 | 649 | 4.620 |
Why?
| | Bone and Bones | 16 | 2021 | 294 | 3.470 |
Why?
| | Postmenopause | 31 | 2020 | 349 | 3.330 |
Why?
| | Parathyroid Hormone | 9 | 2021 | 107 | 3.300 |
Why?
| | Estrogens | 21 | 2024 | 347 | 3.030 |
Why?
| | Menopause | 13 | 2022 | 297 | 3.020 |
Why?
| | Estradiol | 18 | 2024 | 494 | 2.720 |
Why?
| | Bone Resorption | 7 | 2022 | 80 | 2.680 |
Why?
| | Calcium | 7 | 2021 | 1212 | 2.280 |
Why?
| | Premenopause | 11 | 2020 | 120 | 2.260 |
Why?
| | Exercise Therapy | 19 | 2025 | 412 | 2.230 |
Why?
| | Estrogen Replacement Therapy | 16 | 2019 | 137 | 2.210 |
Why?
| | Gonadotropin-Releasing Hormone | 9 | 2024 | 205 | 2.160 |
Why?
| | Energy Metabolism | 16 | 2024 | 875 | 2.010 |
Why?
| | Parkinson Disease | 16 | 2025 | 461 | 1.880 |
Why?
| | Endothelium, Vascular | 11 | 2025 | 903 | 1.850 |
Why?
| | Estrogens, Conjugated (USP) | 9 | 2017 | 46 | 1.850 |
Why?
| | Collagen Type I | 13 | 2021 | 118 | 1.850 |
Why?
| | Walking | 11 | 2021 | 500 | 1.850 |
Why?
| | Resistance Training | 9 | 2024 | 151 | 1.780 |
Why?
| | Calcium, Dietary | 7 | 2017 | 56 | 1.640 |
Why?
| | Middle Aged | 127 | 2025 | 31136 | 1.520 |
Why?
| | Adipose Tissue | 25 | 2022 | 591 | 1.500 |
Why?
| | Osteoporosis, Postmenopausal | 9 | 2019 | 39 | 1.450 |
Why?
| | Dehydroepiandrosterone | 5 | 2018 | 51 | 1.440 |
Why?
| | Lumbar Vertebrae | 11 | 2021 | 234 | 1.430 |
Why?
| | Aged | 113 | 2025 | 22061 | 1.400 |
Why?
| | Femur Neck | 8 | 2020 | 60 | 1.400 |
Why?
| | Aging | 29 | 2025 | 1778 | 1.400 |
Why?
| | Female | 180 | 2025 | 68735 | 1.350 |
Why?
| | Insulin | 26 | 2022 | 2326 | 1.330 |
Why?
| | Ovary | 4 | 2024 | 209 | 1.300 |
Why?
| | Peptides | 12 | 2021 | 926 | 1.280 |
Why?
| | Homeostasis | 7 | 2019 | 605 | 1.230 |
Why?
| | Humans | 234 | 2025 | 129627 | 1.230 |
Why?
| | Bicycling | 9 | 2014 | 116 | 1.210 |
Why?
| | Hormone Replacement Therapy | 9 | 2018 | 93 | 1.200 |
Why?
| | Lipolysis | 6 | 2014 | 41 | 1.180 |
Why?
| | Glucose | 13 | 2024 | 1002 | 1.160 |
Why?
| | Cardiovascular Diseases | 13 | 2024 | 2006 | 1.150 |
Why?
| | Oxygen Consumption | 32 | 2025 | 672 | 1.100 |
Why?
| | Obesity | 21 | 2024 | 2882 | 1.080 |
Why?
| | Absorptiometry, Photon | 19 | 2024 | 248 | 1.060 |
Why?
| | Arthroplasty, Replacement, Knee | 9 | 2017 | 306 | 1.060 |
Why?
| | Muscle, Skeletal | 17 | 2020 | 1613 | 1.050 |
Why?
| | Sleep Deprivation | 5 | 2022 | 171 | 1.010 |
Why?
| | Sleep | 7 | 2022 | 687 | 0.990 |
Why?
| | Adiposity | 5 | 2018 | 504 | 0.970 |
Why?
| | Vasodilation | 9 | 2025 | 476 | 0.970 |
Why?
| | Physical Endurance | 19 | 2015 | 262 | 0.940 |
Why?
| | Motor Activity | 11 | 2015 | 676 | 0.920 |
Why?
| | Follicle Stimulating Hormone | 6 | 2024 | 237 | 0.900 |
Why?
| | Weight Loss | 11 | 2024 | 738 | 0.890 |
Why?
| | Male | 131 | 2025 | 63671 | 0.880 |
Why?
| | Frail Elderly | 6 | 2013 | 120 | 0.870 |
Why?
| | Adult | 88 | 2025 | 35600 | 0.870 |
Why?
| | Muscle Strength | 9 | 2024 | 303 | 0.870 |
Why?
| | Quadriceps Muscle | 5 | 2017 | 129 | 0.860 |
Why?
| | Dehydroepiandrosterone Sulfate | 4 | 2013 | 46 | 0.820 |
Why?
| | Vascular Stiffness | 5 | 2018 | 467 | 0.810 |
Why?
| | Sweating | 2 | 2019 | 40 | 0.800 |
Why?
| | Insulin Resistance | 11 | 2017 | 1167 | 0.780 |
Why?
| | Glycerol | 8 | 2013 | 92 | 0.780 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2018 | 181 | 0.770 |
Why?
| | Adipocytes | 5 | 2022 | 204 | 0.770 |
Why?
| | Double-Blind Method | 13 | 2018 | 1875 | 0.760 |
Why?
| | Pituitary-Adrenal System | 2 | 2018 | 148 | 0.760 |
Why?
| | Brachial Artery | 8 | 2025 | 192 | 0.730 |
Why?
| | Electric Stimulation Therapy | 2 | 2012 | 77 | 0.710 |
Why?
| | Weight-Bearing | 7 | 2017 | 162 | 0.700 |
Why?
| | Bone Remodeling | 6 | 2022 | 71 | 0.700 |
Why?
| | Raloxifene Hydrochloride | 3 | 2017 | 16 | 0.700 |
Why?
| | Trigger Points | 2 | 2018 | 14 | 0.700 |
Why?
| | Subcutaneous Fat | 3 | 2014 | 74 | 0.690 |
Why?
| | Testosterone | 7 | 2025 | 372 | 0.680 |
Why?
| | Sex Factors | 10 | 2024 | 1970 | 0.660 |
Why?
| | Exercise Test | 18 | 2024 | 613 | 0.650 |
Why?
| | Osteoarthritis, Knee | 6 | 2018 | 240 | 0.650 |
Why?
| | Skin | 4 | 2019 | 727 | 0.640 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 2018 | 61 | 0.630 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2021 | 338 | 0.620 |
Why?
| | Activities of Daily Living | 7 | 2020 | 382 | 0.620 |
Why?
| | Lactic Acid | 7 | 2018 | 298 | 0.600 |
Why?
| | Tension-Type Headache | 1 | 2018 | 8 | 0.600 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2024 | 1365 | 0.600 |
Why?
| | Adaptation, Physiological | 4 | 2012 | 514 | 0.600 |
Why?
| | Osteoporosis | 10 | 2024 | 230 | 0.600 |
Why?
| | Headache Disorders | 1 | 2018 | 17 | 0.600 |
Why?
| | Physical Fitness | 9 | 2014 | 203 | 0.590 |
Why?
| | Heart Rate | 20 | 2025 | 802 | 0.580 |
Why?
| | Massage | 1 | 2018 | 43 | 0.580 |
Why?
| | Biomarkers | 16 | 2025 | 3968 | 0.570 |
Why?
| | Weight Gain | 3 | 2011 | 509 | 0.560 |
Why?
| | Regional Blood Flow | 3 | 2018 | 463 | 0.550 |
Why?
| | Immunoglobulin G | 3 | 2021 | 851 | 0.540 |
Why?
| | Leptin | 7 | 2022 | 220 | 0.540 |
Why?
| | Health | 3 | 2017 | 75 | 0.540 |
Why?
| | Hot Temperature | 1 | 2019 | 370 | 0.530 |
Why?
| | Abdomen | 9 | 2005 | 118 | 0.530 |
Why?
| | Blood Glucose | 22 | 2013 | 2100 | 0.530 |
Why?
| | Leuprolide | 2 | 2017 | 19 | 0.520 |
Why?
| | Aged, 80 and over | 24 | 2019 | 7052 | 0.520 |
Why?
| | Ibuprofen | 2 | 2021 | 81 | 0.500 |
Why?
| | Osteogenesis | 5 | 2020 | 173 | 0.500 |
Why?
| | Exercise Tolerance | 4 | 2025 | 273 | 0.500 |
Why?
| | Dietary Supplements | 2 | 2017 | 534 | 0.490 |
Why?
| | Glucose Clamp Technique | 13 | 2014 | 194 | 0.490 |
Why?
| | Medroxyprogesterone Acetate | 5 | 2003 | 35 | 0.480 |
Why?
| | Glucose Tolerance Test | 12 | 2013 | 355 | 0.480 |
Why?
| | Antibodies | 1 | 2017 | 398 | 0.480 |
Why?
| | Severity of Illness Index | 11 | 2018 | 2739 | 0.470 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2017 | 28 | 0.470 |
Why?
| | Medroxyprogesterone | 2 | 2007 | 10 | 0.460 |
Why?
| | Health Status | 4 | 2020 | 756 | 0.450 |
Why?
| | Gonadal Steroid Hormones | 4 | 2021 | 132 | 0.450 |
Why?
| | Young Adult | 20 | 2024 | 12455 | 0.450 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 34 | 0.450 |
Why?
| | Perimenopause | 4 | 2022 | 60 | 0.440 |
Why?
| | Body Weight | 14 | 2024 | 940 | 0.430 |
Why?
| | Thigh | 3 | 2010 | 53 | 0.430 |
Why?
| | Saliva | 2 | 2005 | 211 | 0.420 |
Why?
| | Running | 9 | 2015 | 223 | 0.420 |
Why?
| | Deuterium | 6 | 2019 | 87 | 0.410 |
Why?
| | Femur | 6 | 2018 | 243 | 0.410 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 161 | 0.410 |
Why?
| | Cognition Disorders | 2 | 2015 | 505 | 0.400 |
Why?
| | Sweat | 4 | 2019 | 46 | 0.390 |
Why?
| | Quality of Life | 8 | 2022 | 2688 | 0.390 |
Why?
| | Treatment Outcome | 18 | 2022 | 10219 | 0.380 |
Why?
| | Cognition | 3 | 2013 | 1129 | 0.380 |
Why?
| | Hydrocortisone | 3 | 2018 | 306 | 0.370 |
Why?
| | Heart-Assist Devices | 3 | 2023 | 537 | 0.370 |
Why?
| | Hormone Antagonists | 1 | 2011 | 33 | 0.360 |
Why?
| | Baroreflex | 2 | 2022 | 53 | 0.360 |
Why?
| | Adipose Tissue, Brown | 2 | 2024 | 51 | 0.360 |
Why?
| | Analysis of Variance | 11 | 2018 | 1293 | 0.360 |
Why?
| | Procollagen | 3 | 2020 | 21 | 0.350 |
Why?
| | Physical Education and Training | 14 | 1996 | 75 | 0.350 |
Why?
| | Osteocalcin | 5 | 2022 | 36 | 0.350 |
Why?
| | Body Mass Index | 10 | 2019 | 2274 | 0.350 |
Why?
| | Hip | 6 | 2012 | 55 | 0.350 |
Why?
| | Lipids | 6 | 2013 | 627 | 0.350 |
Why?
| | HIV Infections | 8 | 2020 | 2730 | 0.340 |
Why?
| | Sympathetic Nervous System | 1 | 2011 | 174 | 0.340 |
Why?
| | Carotid Arteries | 5 | 2018 | 196 | 0.340 |
Why?
| | Sex Characteristics | 10 | 2024 | 736 | 0.330 |
Why?
| | Disability Evaluation | 5 | 2013 | 285 | 0.330 |
Why?
| | Acetaminophen | 1 | 2012 | 247 | 0.330 |
Why?
| | Glucose Intolerance | 5 | 2001 | 142 | 0.330 |
Why?
| | Women's Health | 4 | 2024 | 364 | 0.330 |
Why?
| | Vasodilator Agents | 1 | 2012 | 326 | 0.330 |
Why?
| | Bone Density Conservation Agents | 2 | 2024 | 70 | 0.330 |
Why?
| | Gravitation | 1 | 2009 | 15 | 0.330 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 88 | 0.320 |
Why?
| | Menstrual Cycle | 2 | 2013 | 121 | 0.320 |
Why?
| | Osteoarthritis | 2 | 2015 | 168 | 0.320 |
Why?
| | Alkaline Phosphatase | 3 | 2021 | 146 | 0.310 |
Why?
| | Heart Failure | 4 | 2024 | 2133 | 0.310 |
Why?
| | Cross-Sectional Studies | 14 | 2022 | 5075 | 0.300 |
Why?
| | Range of Motion, Articular | 7 | 2017 | 367 | 0.300 |
Why?
| | Adolescent | 15 | 2024 | 20412 | 0.300 |
Why?
| | Progesterone Congeners | 3 | 2003 | 17 | 0.300 |
Why?
| | Dyslipidemias | 1 | 2010 | 177 | 0.300 |
Why?
| | Physical Exertion | 6 | 2001 | 205 | 0.300 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1202 | 0.290 |
Why?
| | Prospective Studies | 16 | 2019 | 7135 | 0.290 |
Why?
| | Urine | 3 | 2004 | 60 | 0.290 |
Why?
| | Circadian Rhythm | 4 | 2020 | 413 | 0.290 |
Why?
| | Ovariectomy | 4 | 2024 | 135 | 0.280 |
Why?
| | High-Intensity Interval Training | 2 | 2018 | 24 | 0.280 |
Why?
| | Pain Measurement | 6 | 2018 | 508 | 0.280 |
Why?
| | Pain Threshold | 3 | 2018 | 79 | 0.270 |
Why?
| | Sports | 5 | 2020 | 225 | 0.270 |
Why?
| | Body Water | 2 | 2004 | 20 | 0.260 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2019 | 3628 | 0.260 |
Why?
| | Area Under Curve | 6 | 2013 | 304 | 0.260 |
Why?
| | Peptide Fragments | 3 | 2020 | 693 | 0.260 |
Why?
| | Hypogonadism | 3 | 2015 | 84 | 0.260 |
Why?
| | Fractures, Bone | 4 | 2016 | 394 | 0.260 |
Why?
| | Triglycerides | 4 | 2011 | 528 | 0.260 |
Why?
| | Postural Balance | 6 | 2015 | 199 | 0.260 |
Why?
| | Risk Factors | 12 | 2019 | 9786 | 0.250 |
Why?
| | Microdialysis | 6 | 2012 | 51 | 0.250 |
Why?
| | Blood Coagulation | 1 | 2007 | 239 | 0.240 |
Why?
| | Radioisotope Dilution Technique | 2 | 2004 | 13 | 0.240 |
Why?
| | Cardiac Output | 5 | 2023 | 156 | 0.240 |
Why?
| | Heart Ventricles | 2 | 2020 | 781 | 0.240 |
Why?
| | Water | 2 | 2019 | 441 | 0.240 |
Why?
| | Cholesterol | 4 | 2011 | 412 | 0.230 |
Why?
| | Bone Marrow Cells | 3 | 2021 | 302 | 0.230 |
Why?
| | Basal Metabolism | 1 | 2005 | 58 | 0.230 |
Why?
| | Alendronate | 1 | 2024 | 15 | 0.230 |
Why?
| | Diet | 8 | 2019 | 1213 | 0.230 |
Why?
| | Time Factors | 14 | 2019 | 6555 | 0.230 |
Why?
| | Body Constitution | 2 | 2001 | 53 | 0.220 |
Why?
| | Oxidative Stress | 4 | 2022 | 1266 | 0.220 |
Why?
| | Recovery of Function | 6 | 2017 | 642 | 0.220 |
Why?
| | Serum | 1 | 2004 | 58 | 0.220 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 205 | 0.220 |
Why?
| | Regression Analysis | 6 | 2011 | 997 | 0.220 |
Why?
| | HIV-1 | 4 | 2013 | 838 | 0.210 |
Why?
| | Blood Pressure | 10 | 2022 | 1736 | 0.210 |
Why?
| | Placebos | 4 | 2011 | 201 | 0.210 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 128 | 0.210 |
Why?
| | Endothelin-1 | 1 | 2025 | 179 | 0.210 |
Why?
| | Caloric Restriction | 1 | 2024 | 111 | 0.210 |
Why?
| | Sports Medicine | 1 | 2004 | 110 | 0.200 |
Why?
| | Adipose Tissue, White | 2 | 2024 | 37 | 0.200 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 49 | 0.200 |
Why?
| | Rats, Wistar | 1 | 2024 | 442 | 0.200 |
Why?
| | Diet, Reducing | 2 | 2001 | 87 | 0.200 |
Why?
| | Cold Temperature | 2 | 2024 | 154 | 0.200 |
Why?
| | Arginine | 4 | 2017 | 263 | 0.190 |
Why?
| | Knee Joint | 6 | 2017 | 374 | 0.190 |
Why?
| | Circadian Clocks | 2 | 2019 | 45 | 0.190 |
Why?
| | Thermogenesis | 2 | 2024 | 44 | 0.190 |
Why?
| | Intermittent Claudication | 2 | 2015 | 118 | 0.190 |
Why?
| | Torque | 2 | 2012 | 82 | 0.190 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2013 | 306 | 0.190 |
Why?
| | Weight Reduction Programs | 2 | 2014 | 110 | 0.190 |
Why?
| | Ventricular Function, Right | 2 | 2020 | 276 | 0.180 |
Why?
| | Ultrasonography | 7 | 2018 | 712 | 0.180 |
Why?
| | Oxygen Isotopes | 2 | 2019 | 22 | 0.180 |
Why?
| | Vitamin D | 3 | 2020 | 381 | 0.180 |
Why?
| | Proteins | 5 | 1998 | 944 | 0.180 |
Why?
| | Intestinal Absorption | 1 | 2001 | 99 | 0.180 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.180 |
Why?
| | Superficial Back Muscles | 2 | 2018 | 14 | 0.180 |
Why?
| | Muscle Proteins | 3 | 2019 | 220 | 0.180 |
Why?
| | Glycosylation | 2 | 2021 | 153 | 0.170 |
Why?
| | Postprandial Period | 1 | 2001 | 104 | 0.170 |
Why?
| | Polysaccharides | 2 | 2021 | 86 | 0.170 |
Why?
| | Hip Joint | 3 | 2019 | 158 | 0.170 |
Why?
| | Dexamethasone | 2 | 2018 | 350 | 0.170 |
Why?
| | Cross-Over Studies | 3 | 2014 | 520 | 0.170 |
Why?
| | Interleukin-6 | 2 | 2022 | 723 | 0.170 |
Why?
| | Pulmonary Gas Exchange | 5 | 2017 | 121 | 0.170 |
Why?
| | Lactates | 8 | 2012 | 86 | 0.170 |
Why?
| | Physical Conditioning, Animal | 4 | 2019 | 229 | 0.170 |
Why?
| | Luteal Phase | 2 | 2014 | 44 | 0.170 |
Why?
| | Pilot Projects | 6 | 2020 | 1592 | 0.170 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2023 | 385 | 0.170 |
Why?
| | Carbohydrate Metabolism | 3 | 1998 | 62 | 0.170 |
Why?
| | Age Factors | 7 | 2025 | 3152 | 0.170 |
Why?
| | Research Design | 4 | 2024 | 1045 | 0.170 |
Why?
| | Animals | 22 | 2024 | 35391 | 0.160 |
Why?
| | Oxidation-Reduction | 5 | 2020 | 1028 | 0.160 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 25 | 0.160 |
Why?
| | Surveys and Questionnaires | 8 | 2019 | 5415 | 0.160 |
Why?
| | Reference Values | 6 | 2013 | 794 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 221 | 0.160 |
Why?
| | Patient Compliance | 4 | 2015 | 565 | 0.160 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 37 | 0.160 |
Why?
| | Coronary Disease | 2 | 2001 | 385 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2020 | 335 | 0.160 |
Why?
| | Geographic Atrophy | 1 | 2019 | 69 | 0.150 |
Why?
| | Health Behavior | 1 | 2004 | 743 | 0.150 |
Why?
| | Cholesterol, LDL | 4 | 2011 | 358 | 0.150 |
Why?
| | Acidosis | 1 | 2019 | 89 | 0.150 |
Why?
| | Case-Control Studies | 7 | 2019 | 3378 | 0.150 |
Why?
| | Compliance | 2 | 2018 | 44 | 0.150 |
Why?
| | Calcium Channels, L-Type | 1 | 2019 | 117 | 0.150 |
Why?
| | Homocysteine | 1 | 2019 | 152 | 0.150 |
Why?
| | Extracellular Fluid | 1 | 2018 | 31 | 0.150 |
Why?
| | Cortisone | 1 | 2018 | 11 | 0.150 |
Why?
| | Proof of Concept Study | 1 | 2018 | 69 | 0.150 |
Why?
| | Swimming | 2 | 1989 | 48 | 0.150 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2019 | 187 | 0.150 |
Why?
| | Ions | 1 | 2018 | 66 | 0.150 |
Why?
| | Cancellous Bone | 1 | 2017 | 21 | 0.140 |
Why?
| | Macular Degeneration | 1 | 2019 | 159 | 0.140 |
Why?
| | Osteoarthritis, Hip | 1 | 2018 | 43 | 0.140 |
Why?
| | Obesity, Abdominal | 2 | 2017 | 47 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 195 | 0.140 |
Why?
| | Cardiovascular Physiological Phenomena | 3 | 2015 | 41 | 0.140 |
Why?
| | omega-N-Methylarginine | 1 | 1997 | 26 | 0.140 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 294 | 0.140 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 133 | 0.140 |
Why?
| | Rest | 2 | 1997 | 120 | 0.140 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 231 | 0.140 |
Why?
| | Integrin beta1 | 1 | 2017 | 22 | 0.140 |
Why?
| | Isotope Labeling | 1 | 2017 | 74 | 0.140 |
Why?
| | Growth Hormone | 1 | 1997 | 96 | 0.140 |
Why?
| | Galactose | 1 | 2017 | 27 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2019 | 2442 | 0.130 |
Why?
| | Forearm | 1 | 1997 | 117 | 0.130 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 120 | 0.130 |
Why?
| | Luteinizing Hormone | 2 | 2015 | 178 | 0.130 |
Why?
| | Hypokinesia | 1 | 2016 | 8 | 0.130 |
Why?
| | Healthy Volunteers | 2 | 2017 | 201 | 0.130 |
Why?
| | Lipid Metabolism | 3 | 1998 | 503 | 0.130 |
Why?
| | Electromyography | 2 | 2016 | 381 | 0.130 |
Why?
| | Peripheral Arterial Disease | 2 | 2015 | 458 | 0.130 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 43 | 0.130 |
Why?
| | Osteoporotic Fractures | 1 | 2017 | 56 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2019 | 240 | 0.130 |
Why?
| | Hyperinsulinism | 3 | 2003 | 119 | 0.130 |
Why?
| | Food, Fortified | 1 | 2016 | 37 | 0.130 |
Why?
| | Administration, Cutaneous | 3 | 2015 | 124 | 0.130 |
Why?
| | Stroke Volume | 6 | 2023 | 592 | 0.130 |
Why?
| | Energy Intake | 5 | 2013 | 462 | 0.120 |
Why?
| | Adipocytes, White | 1 | 2015 | 17 | 0.120 |
Why?
| | Pelvic Bones | 1 | 2018 | 156 | 0.120 |
Why?
| | Gonadotropins | 1 | 2015 | 38 | 0.120 |
Why?
| | Pain | 1 | 2001 | 787 | 0.120 |
Why?
| | Muscle Strength Dynamometer | 2 | 2012 | 22 | 0.120 |
Why?
| | Aging, Premature | 2 | 2013 | 13 | 0.120 |
Why?
| | Nitric Oxide | 2 | 2017 | 895 | 0.120 |
Why?
| | Precision Medicine | 1 | 2019 | 387 | 0.120 |
Why?
| | Predictive Value of Tests | 4 | 2015 | 1947 | 0.120 |
Why?
| | Injections, Intravenous | 2 | 2006 | 202 | 0.120 |
Why?
| | Stem Cells | 2 | 2017 | 575 | 0.120 |
Why?
| | Metabolomics | 1 | 2020 | 653 | 0.120 |
Why?
| | Muscles | 7 | 2013 | 320 | 0.110 |
Why?
| | Wrist Joint | 1 | 1995 | 64 | 0.110 |
Why?
| | Accidental Falls | 2 | 2017 | 169 | 0.110 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 1005 | 0.110 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 757 | 0.110 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2012 | 171 | 0.110 |
Why?
| | Mice | 7 | 2022 | 16961 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 2512 | 0.110 |
Why?
| | Linear Models | 2 | 2008 | 819 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2017 | 714 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2011 | 0.110 |
Why?
| | Etanercept | 1 | 2013 | 56 | 0.110 |
Why?
| | Neck Pain | 1 | 2013 | 27 | 0.110 |
Why?
| | Spine | 1 | 1995 | 160 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2720 | 0.100 |
Why?
| | Catecholamines | 1 | 1993 | 96 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2018 | 4894 | 0.100 |
Why?
| | Radiography | 2 | 2012 | 797 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 126 | 0.100 |
Why?
| | Health Status Indicators | 2 | 2011 | 166 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 228 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 231 | 0.100 |
Why?
| | Life Style | 3 | 2008 | 461 | 0.100 |
Why?
| | Microfluidics | 1 | 2013 | 52 | 0.100 |
Why?
| | Sensitivity and Specificity | 3 | 2005 | 1843 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 2022 | 400 | 0.100 |
Why?
| | Mathematical Concepts | 1 | 2013 | 26 | 0.100 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2013 | 53 | 0.100 |
Why?
| | Acupressure | 1 | 2012 | 4 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 3 | 2022 | 382 | 0.100 |
Why?
| | Hunger | 1 | 2013 | 42 | 0.100 |
Why?
| | Femoral Neck Fractures | 1 | 2012 | 22 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 342 | 0.100 |
Why?
| | Steroids | 1 | 2013 | 158 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1042 | 0.100 |
Why?
| | Myofascial Pain Syndromes | 1 | 2012 | 13 | 0.100 |
Why?
| | Posture | 1 | 1993 | 175 | 0.100 |
Why?
| | Carbon Isotopes | 2 | 2006 | 126 | 0.100 |
Why?
| | Neuropsychological Tests | 2 | 2015 | 1017 | 0.100 |
Why?
| | Hemodynamics | 4 | 2023 | 1090 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 57 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2012 | 49 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 74 | 0.090 |
Why?
| | Incidence | 3 | 2019 | 2641 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 118 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 247 | 0.090 |
Why?
| | Gait | 4 | 2015 | 280 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2012 | 119 | 0.090 |
Why?
| | Oxytocics | 1 | 2011 | 13 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 83 | 0.090 |
Why?
| | Meals | 1 | 2013 | 119 | 0.090 |
Why?
| | Headache | 1 | 2012 | 151 | 0.090 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 423 | 0.090 |
Why?
| | Cartilage, Articular | 1 | 2015 | 292 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 5 | 2001 | 160 | 0.090 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 228 | 0.090 |
Why?
| | Muscle Fatigue | 1 | 2012 | 99 | 0.090 |
Why?
| | Longevity | 2 | 2024 | 155 | 0.090 |
Why?
| | Perception | 2 | 2013 | 344 | 0.090 |
Why?
| | Kinetics | 5 | 2003 | 1645 | 0.090 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1203 | 0.090 |
Why?
| | Dinoprostone | 1 | 2011 | 187 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 515 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5455 | 0.090 |
Why?
| | Athletes | 1 | 2014 | 411 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 1999 | 1221 | 0.090 |
Why?
| | Single-Blind Method | 3 | 2016 | 271 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 523 | 0.080 |
Why?
| | Parity | 1 | 2010 | 120 | 0.080 |
Why?
| | Cohort Studies | 2 | 2012 | 5426 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2022 | 375 | 0.080 |
Why?
| | Contraceptive Agents | 1 | 2010 | 65 | 0.080 |
Why?
| | Depression | 1 | 2018 | 1317 | 0.080 |
Why?
| | Androgens | 2 | 2017 | 177 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 764 | 0.080 |
Why?
| | Chronic Pain | 1 | 2013 | 253 | 0.080 |
Why?
| | Antiparkinson Agents | 2 | 2022 | 28 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2013 | 1058 | 0.080 |
Why?
| | Advance Care Planning | 1 | 2012 | 200 | 0.080 |
Why?
| | Efficiency | 1 | 1989 | 91 | 0.080 |
Why?
| | Respiration | 4 | 2015 | 192 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 2 | 2019 | 57 | 0.080 |
Why?
| | Rats | 8 | 2024 | 5483 | 0.080 |
Why?
| | Carbon Dioxide | 2 | 2010 | 259 | 0.080 |
Why?
| | Muscle Contraction | 1 | 2011 | 423 | 0.080 |
Why?
| | Calcium Citrate | 1 | 2008 | 1 | 0.070 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 111 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2009 | 305 | 0.070 |
Why?
| | Executive Function | 1 | 2013 | 432 | 0.070 |
Why?
| | Spectrum Analysis | 2 | 2019 | 89 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 767 | 0.070 |
Why?
| | Dietary Fats | 4 | 2013 | 301 | 0.070 |
Why?
| | Cytokines | 1 | 2015 | 2021 | 0.070 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 528 | 0.070 |
Why?
| | Low Back Pain | 1 | 2008 | 106 | 0.070 |
Why?
| | Norepinephrine | 2 | 2021 | 210 | 0.070 |
Why?
| | Leg | 3 | 2002 | 239 | 0.070 |
Why?
| | Cell Differentiation | 3 | 2021 | 1891 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1499 | 0.070 |
Why?
| | Carrier Proteins | 2 | 2005 | 745 | 0.070 |
Why?
| | Electric Stimulation | 1 | 2007 | 267 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2008 | 209 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1418 | 0.060 |
Why?
| | Densitometry | 2 | 1998 | 34 | 0.060 |
Why?
| | Radioimmunoassay | 1 | 2005 | 175 | 0.060 |
Why?
| | Buttocks | 1 | 2005 | 12 | 0.060 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 167 | 0.060 |
Why?
| | Follicular Phase | 1 | 2005 | 38 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 212 | 0.060 |
Why?
| | Cell Lineage | 2 | 2017 | 331 | 0.060 |
Why?
| | Nutritional Status | 2 | 2019 | 329 | 0.060 |
Why?
| | Calorimetry, Indirect | 2 | 2017 | 81 | 0.060 |
Why?
| | Colorado | 4 | 2019 | 4404 | 0.060 |
Why?
| | Logistic Models | 2 | 2019 | 1986 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 787 | 0.050 |
Why?
| | Plethysmography | 2 | 2022 | 106 | 0.050 |
Why?
| | Endometrium | 1 | 2003 | 56 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2019 | 14522 | 0.050 |
Why?
| | Liver | 3 | 2024 | 1842 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2015 | 419 | 0.050 |
Why?
| | Models, Animal | 1 | 2004 | 378 | 0.050 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 37 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2627 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 267 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 93 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 47 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 282 | 0.050 |
Why?
| | Skinfold Thickness | 2 | 1992 | 46 | 0.050 |
Why?
| | Preoperative Period | 2 | 2014 | 115 | 0.050 |
Why?
| | Diphtheria Toxin | 1 | 2022 | 65 | 0.050 |
Why?
| | Food Deprivation | 2 | 2000 | 21 | 0.050 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 110 | 0.050 |
Why?
| | Knee | 2 | 1997 | 63 | 0.050 |
Why?
| | Osteocytes | 1 | 2001 | 27 | 0.050 |
Why?
| | Lipoproteins | 2 | 2000 | 172 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1269 | 0.050 |
Why?
| | Eating | 2 | 2001 | 368 | 0.050 |
Why?
| | Movement | 2 | 2014 | 270 | 0.050 |
Why?
| | Postoperative Period | 2 | 2014 | 330 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 286 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2002 | 126 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 118 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 8 | 0.040 |
Why?
| | Signal Transduction | 2 | 2021 | 4931 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2005 | 580 | 0.040 |
Why?
| | Tibia | 2 | 2019 | 172 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 467 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 64 | 0.040 |
Why?
| | Musculoskeletal Physiological Phenomena | 1 | 2000 | 8 | 0.040 |
Why?
| | Kidney | 2 | 1998 | 1386 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 235 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2022 | 406 | 0.040 |
Why?
| | Child Development | 1 | 1985 | 460 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 170 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2128 | 0.040 |
Why?
| | Electric Conductivity | 1 | 2019 | 94 | 0.040 |
Why?
| | Blood Circulation | 1 | 1999 | 41 | 0.040 |
Why?
| | Fasting | 1 | 2001 | 267 | 0.040 |
Why?
| | Orchiectomy | 1 | 2019 | 67 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 91 | 0.040 |
Why?
| | Electrocardiography | 2 | 2020 | 611 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 113 | 0.040 |
Why?
| | Muscle Development | 1 | 2000 | 103 | 0.040 |
Why?
| | Anthropometry | 2 | 2017 | 204 | 0.040 |
Why?
| | Radius | 1 | 2019 | 36 | 0.040 |
Why?
| | Collagen | 1 | 2001 | 435 | 0.040 |
Why?
| | Physician's Role | 1 | 2001 | 206 | 0.040 |
Why?
| | Attitude | 1 | 2001 | 253 | 0.040 |
Why?
| | Actigraphy | 1 | 2019 | 98 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 558 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 216 | 0.040 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 39 | 0.040 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 46 | 0.040 |
Why?
| | Feasibility Studies | 2 | 2015 | 869 | 0.040 |
Why?
| | Socioeconomic Factors | 2 | 2013 | 1213 | 0.040 |
Why?
| | North Carolina | 1 | 2018 | 98 | 0.040 |
Why?
| | Isometric Contraction | 2 | 2010 | 185 | 0.040 |
Why?
| | Administration, Topical | 1 | 2018 | 147 | 0.040 |
Why?
| | Conservative Treatment | 1 | 2018 | 32 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 130 | 0.040 |
Why?
| | Transcriptome | 1 | 2024 | 876 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 136 | 0.040 |
Why?
| | Mental Health | 2 | 2015 | 688 | 0.040 |
Why?
| | Ventricular Remodeling | 1 | 2000 | 255 | 0.040 |
Why?
| | Pregnancy | 1 | 2010 | 6417 | 0.040 |
Why?
| | Hamstring Muscles | 1 | 2017 | 17 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 399 | 0.030 |
Why?
| | Nephrectomy | 1 | 1998 | 158 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 7 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 1989 | 3394 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 19 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 520 | 0.030 |
Why?
| | Blood | 2 | 1995 | 105 | 0.030 |
Why?
| | Psychometrics | 1 | 2001 | 696 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 1997 | 97 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 51 | 0.030 |
Why?
| | Adipogenesis | 1 | 2017 | 51 | 0.030 |
Why?
| | Cell Size | 1 | 1996 | 87 | 0.030 |
Why?
| | Fibrin | 1 | 2017 | 68 | 0.030 |
Why?
| | Joints | 1 | 1997 | 101 | 0.030 |
Why?
| | Child | 3 | 2024 | 20884 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 226 | 0.030 |
Why?
| | Heart | 1 | 2020 | 641 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 93 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 51 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 49 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 1998 | 264 | 0.030 |
Why?
| | Glycogen | 1 | 1996 | 55 | 0.030 |
Why?
| | Affect | 1 | 2018 | 288 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2017 | 142 | 0.030 |
Why?
| | Mental Status Schedule | 1 | 2015 | 34 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2784 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.030 |
Why?
| | Fatty Acids | 1 | 1998 | 427 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 175 | 0.030 |
Why?
| | Capillaries | 1 | 1996 | 103 | 0.030 |
Why?
| | Calibration | 1 | 1995 | 140 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 1995 | 71 | 0.030 |
Why?
| | Neurophysiology | 1 | 2015 | 10 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 68 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 625 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 325 | 0.030 |
Why?
| | Databases, Bibliographic | 1 | 2015 | 30 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2001 | 514 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 799 | 0.030 |
Why?
| | Arthrometry, Articular | 1 | 2014 | 10 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 506 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3080 | 0.030 |
Why?
| | Progesterone | 1 | 2015 | 245 | 0.030 |
Why?
| | Models, Biological | 2 | 1999 | 1724 | 0.030 |
Why?
| | Cholesterol Esters | 1 | 1993 | 7 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 2014 | 120 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 38 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2015 | 260 | 0.030 |
Why?
| | United States | 1 | 2010 | 13871 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 49 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 21 | 0.030 |
Why?
| | Citrates | 1 | 1993 | 42 | 0.030 |
Why?
| | Epinephrine | 1 | 1993 | 141 | 0.030 |
Why?
| | Comorbidity | 1 | 1998 | 1547 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 66 | 0.030 |
Why?
| | Anaerobic Threshold | 1 | 1992 | 28 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 64 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2564 | 0.020 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 179 | 0.020 |
Why?
| | Appetite | 1 | 2013 | 61 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2012 | 93 | 0.020 |
Why?
| | Upper Extremity | 1 | 2013 | 95 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2013 | 151 | 0.020 |
Why?
| | Somatomedins | 1 | 1991 | 28 | 0.020 |
Why?
| | Registries | 1 | 2019 | 1899 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2013 | 129 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 637 | 0.020 |
Why?
| | Apolipoproteins B | 1 | 1991 | 43 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 386 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 576 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 317 | 0.020 |
Why?
| | Glycoproteins | 1 | 1993 | 338 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 205 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 267 | 0.020 |
Why?
| | Disabled Persons | 1 | 2013 | 140 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1207 | 0.020 |
Why?
| | Viral Load | 1 | 2013 | 449 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 223 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 55 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1243 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 596 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 875 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 477 | 0.020 |
Why?
| | Glycogen Storage Disease Type V | 1 | 1990 | 1 | 0.020 |
Why?
| | Hyperglycemia | 2 | 1991 | 327 | 0.020 |
Why?
| | Physical Phenomena | 1 | 2010 | 13 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 334 | 0.020 |
Why?
| | Blood Vessels | 1 | 1991 | 187 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2542 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1019 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4084 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 324 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 531 | 0.020 |
Why?
| | Macrophages | 1 | 2017 | 1488 | 0.020 |
Why?
| | Spirometry | 1 | 2010 | 255 | 0.020 |
Why?
| | Body Temperature | 1 | 2010 | 212 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1109 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 3 | 2000 | 2395 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1035 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3262 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 581 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4078 | 0.020 |
Why?
| | Iodine Radioisotopes | 2 | 1998 | 142 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2008 | 219 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 1987 | 32 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 855 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 63 | 0.020 |
Why?
| | Neoplasms | 1 | 2001 | 2455 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 173 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3774 | 0.020 |
Why?
| | DNA | 1 | 2012 | 1404 | 0.010 |
Why?
| | Shoes | 1 | 1985 | 18 | 0.010 |
Why?
| | Aerobiosis | 1 | 1985 | 22 | 0.010 |
Why?
| | Orthotic Devices | 1 | 1985 | 23 | 0.010 |
Why?
| | Body Height | 1 | 1985 | 192 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2008 | 737 | 0.010 |
Why?
| | Endometrial Hyperplasia | 1 | 2003 | 8 | 0.010 |
Why?
| | Uterine Hemorrhage | 1 | 2003 | 33 | 0.010 |
Why?
| | Inflammation | 1 | 2013 | 2750 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2477 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2004 | 317 | 0.010 |
Why?
| | Vascular Resistance | 2 | 1993 | 371 | 0.010 |
Why?
| | Infusions, Intravenous | 2 | 1991 | 399 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2000 | 40 | 0.010 |
Why?
| | Isoflavones | 1 | 1999 | 25 | 0.010 |
Why?
| | Biopsy | 1 | 2003 | 1088 | 0.010 |
Why?
| | Hindlimb | 1 | 2000 | 120 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2000 | 126 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1999 | 136 | 0.010 |
Why?
| | Vibration | 1 | 1999 | 69 | 0.010 |
Why?
| | Organ Size | 1 | 2000 | 446 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 195 | 0.010 |
Why?
| | Uterus | 1 | 2000 | 207 | 0.010 |
Why?
| | Acoustic Stimulation | 1 | 1999 | 329 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 117 | 0.010 |
Why?
| | Analgesics | 1 | 1999 | 191 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 315 | 0.010 |
Why?
| | Creatinine | 1 | 1998 | 490 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 1996 | 39 | 0.010 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 1993 | 18 | 0.010 |
Why?
| | Citric Acid | 1 | 1993 | 30 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1993 | 166 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1992 | 57 | 0.010 |
Why?
| | Breath Tests | 1 | 1992 | 87 | 0.010 |
Why?
| | Cell Membrane | 1 | 1996 | 734 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1991 | 78 | 0.010 |
Why?
| | Hormones | 1 | 1992 | 141 | 0.010 |
Why?
| | Mitochondria, Muscle | 1 | 1992 | 111 | 0.010 |
Why?
| | Glucosephosphates | 1 | 1990 | 3 | 0.010 |
Why?
| | Glucose-6-Phosphate | 1 | 1990 | 6 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 102 | 0.010 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 1990 | 23 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 1990 | 2 | 0.010 |
Why?
| | C-Peptide | 1 | 1991 | 163 | 0.010 |
Why?
| | Lipoproteins, HDL | 1 | 1990 | 85 | 0.010 |
Why?
| | Heart Diseases | 1 | 1993 | 352 | 0.000 |
Why?
| | Fatigue | 1 | 1991 | 318 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1990 | 541 | 0.000 |
Why?
| | Erythrocyte Volume | 1 | 1987 | 6 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1987 | 8 | 0.000 |
Why?
| | Plasma Volume | 1 | 1987 | 19 | 0.000 |
Why?
| | Oxygen | 1 | 1985 | 915 | 0.000 |
Why?
|
|
Kohrt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|